WBR0096: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (refreshing WBR questions)
 
(19 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor=William J Gibson
|QuestionAuthor=William J Gibson (Reviewed by  {{YD}})
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Genetics
|MainCategory=Genetics
Line 8: Line 8:
|MainCategory=Genetics
|MainCategory=Genetics
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Genetics
|MainCategory=Genetics
|MainCategory=Genetics
|MainCategory=Genetics
|MainCategory=Genetics
Line 20: Line 21:
|MainCategory=Genetics
|MainCategory=Genetics
|SubCategory=Cardiology
|SubCategory=Cardiology
|Prompt=A 20 year old male presents to the emergency room with the sudden onset of severe substernal chest pain. His EKG shows ST segment elevation in leads V1-V4.  He denies recent physical trauma and illicit drug use.  The patient has an otherwise normal medical history. Laboratory values show elevated troponin, normal CK-MB, LDL of 340 and HDL of 30. Which of the following is most likely true of this patient’s condition?
|Prompt=A 20-year-old man presents to the emergency department (ED) with an acute severe substernal chest pain at rest. The patient denies recent physical trauma or illicit drug use. His past medical history is unremarkable. His father died of cardiovascular disease at young age, and his mother was recently diagnosed with lung cancer. In the ED, the patient is afebrile, blood pressure is 175/90 mmHg, heart rate is 110/min, and respiratory rate is 22/min. His ECG shows ST-segment elevation in leads V1-V4. Laboratory values show elevated troponin, LDL-cholesterol of 840 mg/dL, and HDL-cholesterol of 30 mg/dL. Which of the following is most likely true of this patient’s condition?
|Explanation=The patient in this vignette most likely suffers from familial hypercholesterolemia.  Familial hypercholesterolemia is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein(LDL, "bad cholesterol"), in the blood and early cardiovascular disease. Many patients have mutations in the LDLR gene that encodes the LDL receptor protein, which normally removes LDL from the circulation. Heterozygous FH is normally treated with statins, bile acid sequestrants or other hypolipidemic agents that lower cholesterol levels. Cholesterol may be deposited in various places in the body that are visible from the outside, such as in yellowish patches around the eyelids (xanthelasma palpebrarum), the outer margin of the iris (arcus senilis corneae) and in the form of lumps in the tendons of the hands, elbows, knees and feet, particularly the Achilles tendon (tendon xanthoma). Accelerated deposition of cholesterol in the walls of arteries leads to atherosclerosis, the underlying cause of cardiovascular disease. These individuals may have premature cardiovascular disease at the age of 30 to 40.
|Explanation=[[Familial hypercholesterolemia]] or familial dyslipidemia type IIa is an autosomal dominant genetic disorder characterized by high concentrations of total cholesterol and plasma low-density lipoprotein (LDL). Patients with the homozygous form typically have LDL concentration > 500 mg/dL, decreased plasma HDL concentration, and increased apoB turnover. Familial hypercholesterolemia is associated with early cardiovascular and peripheral vascular disease, starting in the first or second decade of life.  
 
Patients classically have mutations in the ''LDLR'' gene, which encodes the [[LDL receptor]] protein that normally eliminates LDL from the circulation. Heterozygous familial hypercholesterolemia is usually treated with [[statins]], bile acid sequestrants, or other hypolipidemic agents that lower cholesterol concentration. Individuals with homozygous mutations are more difficult to treat as these individuals lack any functional LDL receptors, which [[statins]] could serve to upregulate. However, these patients may still be prescribed statins and other lipid-lowering agents, along with LDL apheresis. Lomitapide and mipomersen are two drugs recently approved for patients with homozygous familial hypercholesterolemia. Unlike statins, both drugs decrease LDL independently of LDL-receptor activity. Patients may eventually require [[liver transplantation]].
 
Yellow [[cholesterol]] deposits may be observed on the eyelids, leading to the formation of [[xanthelasmas|xanthelasma palpebrarum]]. Additionally, [[xanthoma]]s are subcutaneous fatty deposits in the tendons of the hands, elbows, knees and feet, and characteristically at the distal one-third of the Achilles tendon. The eyes may also be involved in patients with familial hypercholesterolemia, showing arcus senilis corneae, a whitish arc at the edge of the cornea. Accelerated deposition of cholesterol in the walls of arteries leads to premature [[atherosclerosis]], the underlying cause of early cardiovascular and peripheral vascular disease.
|AnswerA=The disease follows autosomal recessive inheritance
|AnswerAExp=[[Familial hypercholesterolemia]] is caused by loss of function mutations in the LDL receptor and follows an [[autosomal dominant]] pattern of inheritance.
|AnswerB=The disease is associated with subcutaneous deposits
|AnswerBExp=[[Familial hypercholesterolemia]] causes an increase in LDL cholesterol, which leads to the formation of subcutaneous fatty [[xanthoma]]s of the [[Achilles tendon]] and [[xanthelasma]]s on the eyelids.
|AnswerC=The disease is associated with hepatomegaly
|AnswerCExp=[[Hyperchylomicronemia]], [[dyslipidemia]] type I, is associated with [[hepatomegaly]].
|AnswerD=The disease is associated with increased chylomicrons
|AnswerDExp=This patient has familial hypercholesterolemia ([[type IIa dyslipidemia]]), which is associated with increased levels of cholesterol in the blood. Patients with hyperchylomycronemia ([[type I dyslipidemia]]) have increased levels of serum [[chylomicrons]].
|AnswerE=The disease is caused by gain-of-function mutations in HMG-CoA reductase
|AnswerEExp=[[Familial hypercholesterolemia]] is caused by loss-of-function mutations in the LDL receptor and follows an [[autosomal dominant]] pattern of inheritance.
|EducationalObjectives=[[Familial hypercholesterolemia]] causes an increase in LDL cholesterol, which leads to the formation of subcutaneous fatty [[xanthoma]]s of the [[Achilles tendon]] and [[xanthelasma]]s on the eyelids.
|References=France M, Schofield J, Kwok S, et al. Treatment of homozygous familial hypercholesterolemia. Clin Lipidol. 2014;9(1):101-18


'''Educational Objective:''' Familial hypercholesterolemia causes increased cholesterol in the blood which can cause subcutaneous deposits (xanthomas) in the achilles tendon and eyelid in particular.
Ziajka PE. Management of patients with homozygous familial hypercholesterolemia. Am J Manag Care. 2013;19(13 Suppl):s


'''References:''' First Aid 2012 page 90,121
First Aid 2014 page 110, 118
|AnswerA=Follows autosomal recessive inheritance
|AnswerAExp='''Incorrect:''' familial hypercholesterolemia is caused by loss of function mutations in the LDL Receptor and follows an autosomal dominant pattern of inheritance.
|AnswerB=Associated with achilles tendon xanthomas
|AnswerBExp='''Correct:''' Familial hypercholesterolemia causes increased cholesterol in the blood which can cause subcutaneous deposits in the achilles tendon and eyelid in particular.
|AnswerC=Associated with hepatosplenomegaly
|AnswerCExp='''Incorrect:''' This is true of hyperchylomicronemia, a separate dyslipidemia.
|AnswerD=Associated with increased chylomicrons
|AnswerDExp='''Incorrect:''' Familial hypercholesterolemia (Type IIa dyslipidemia) is associated with increased levels of cholesterol in the blood.
|AnswerE=Caused by gain of function mutations in HMG-CoA reductase
|AnswerEExp='''Incorrect:''' familial hypercholesterolemia is caused by loss of function mutations in the LDL Receptor and follows an autosomal dominant pattern of inheritance.
|RightAnswer=B
|RightAnswer=B
|WBRKeyword=Familial hypercholesterolemia, Dysplipidemia, Lipids, Cholesterol, Heart, Cardiovascular, Genetics, Myocardial infarction, Atherosclerosis, WJG
|Approved=Yes
|Approved=Yes
}}
}}

Latest revision as of 23:20, 27 October 2020

 
Author [[PageAuthor::William J Gibson (Reviewed by Yazan Daaboul, M.D.)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Genetics
Sub Category SubCategory::Cardiology
Prompt [[Prompt::A 20-year-old man presents to the emergency department (ED) with an acute severe substernal chest pain at rest. The patient denies recent physical trauma or illicit drug use. His past medical history is unremarkable. His father died of cardiovascular disease at young age, and his mother was recently diagnosed with lung cancer. In the ED, the patient is afebrile, blood pressure is 175/90 mmHg, heart rate is 110/min, and respiratory rate is 22/min. His ECG shows ST-segment elevation in leads V1-V4. Laboratory values show elevated troponin, LDL-cholesterol of 840 mg/dL, and HDL-cholesterol of 30 mg/dL. Which of the following is most likely true of this patient’s condition?]]
Answer A AnswerA::The disease follows autosomal recessive inheritance
Answer A Explanation [[AnswerAExp::Familial hypercholesterolemia is caused by loss of function mutations in the LDL receptor and follows an autosomal dominant pattern of inheritance.]]
Answer B AnswerB::The disease is associated with subcutaneous deposits
Answer B Explanation [[AnswerBExp::Familial hypercholesterolemia causes an increase in LDL cholesterol, which leads to the formation of subcutaneous fatty xanthomas of the Achilles tendon and xanthelasmas on the eyelids.]]
Answer C AnswerC::The disease is associated with hepatomegaly
Answer C Explanation [[AnswerCExp::Hyperchylomicronemia, dyslipidemia type I, is associated with hepatomegaly.]]
Answer D AnswerD::The disease is associated with increased chylomicrons
Answer D Explanation [[AnswerDExp::This patient has familial hypercholesterolemia (type IIa dyslipidemia), which is associated with increased levels of cholesterol in the blood. Patients with hyperchylomycronemia (type I dyslipidemia) have increased levels of serum chylomicrons.]]
Answer E AnswerE::The disease is caused by gain-of-function mutations in HMG-CoA reductase
Answer E Explanation [[AnswerEExp::Familial hypercholesterolemia is caused by loss-of-function mutations in the LDL receptor and follows an autosomal dominant pattern of inheritance.]]
Right Answer RightAnswer::B
Explanation [[Explanation::Familial hypercholesterolemia or familial dyslipidemia type IIa is an autosomal dominant genetic disorder characterized by high concentrations of total cholesterol and plasma low-density lipoprotein (LDL). Patients with the homozygous form typically have LDL concentration > 500 mg/dL, decreased plasma HDL concentration, and increased apoB turnover. Familial hypercholesterolemia is associated with early cardiovascular and peripheral vascular disease, starting in the first or second decade of life.

Patients classically have mutations in the LDLR gene, which encodes the LDL receptor protein that normally eliminates LDL from the circulation. Heterozygous familial hypercholesterolemia is usually treated with statins, bile acid sequestrants, or other hypolipidemic agents that lower cholesterol concentration. Individuals with homozygous mutations are more difficult to treat as these individuals lack any functional LDL receptors, which statins could serve to upregulate. However, these patients may still be prescribed statins and other lipid-lowering agents, along with LDL apheresis. Lomitapide and mipomersen are two drugs recently approved for patients with homozygous familial hypercholesterolemia. Unlike statins, both drugs decrease LDL independently of LDL-receptor activity. Patients may eventually require liver transplantation.

Yellow cholesterol deposits may be observed on the eyelids, leading to the formation of xanthelasma palpebrarum. Additionally, xanthomas are subcutaneous fatty deposits in the tendons of the hands, elbows, knees and feet, and characteristically at the distal one-third of the Achilles tendon. The eyes may also be involved in patients with familial hypercholesterolemia, showing arcus senilis corneae, a whitish arc at the edge of the cornea. Accelerated deposition of cholesterol in the walls of arteries leads to premature atherosclerosis, the underlying cause of early cardiovascular and peripheral vascular disease.
Educational Objective: Familial hypercholesterolemia causes an increase in LDL cholesterol, which leads to the formation of subcutaneous fatty xanthomas of the Achilles tendon and xanthelasmas on the eyelids.
References: France M, Schofield J, Kwok S, et al. Treatment of homozygous familial hypercholesterolemia. Clin Lipidol. 2014;9(1):101-18

Ziajka PE. Management of patients with homozygous familial hypercholesterolemia. Am J Manag Care. 2013;19(13 Suppl):s

First Aid 2014 page 110, 118]]

Approved Approved::Yes
Keyword WBRKeyword::Familial hypercholesterolemia, WBRKeyword::Dysplipidemia, WBRKeyword::Lipids, WBRKeyword::Cholesterol, WBRKeyword::Heart, WBRKeyword::Cardiovascular, WBRKeyword::Genetics, WBRKeyword::Myocardial infarction, WBRKeyword::Atherosclerosis, WBRKeyword::WJG
Linked Question Linked::
Order in Linked Questions LinkedOrder::